47 results on '"Russell, Mark"'
Search Results
2. The impact of damaging epilepsy and cardiac genetic variant burden in sudden death in the young
- Author
-
Puckelwartz, Megan J., Pesce, Lorenzo L., Hernandez, Edgar J., Webster, Gregory, Dellefave-Castillo, Lisa M., Russell, Mark W., Geisler, Sarah S., Kearns, Samuel D., Karthik, Felix, Etheridge, Susan P., Monroe, Tanner O., Pottinger, Tess D., Kannankeril, Prince J., Shoemaker, M. Benjamin, Fountain, Darlene, Roden, Dan M., Faulkner, Meghan, MacLeod, Heather M., Burns, Kristin M., Yandell, Mark, Tristani-Firouzi, Martin, George, Jr., Alfred L., and McNally, Elizabeth M.
- Published
- 2024
- Full Text
- View/download PDF
3. STOP THE TRAIN BEFORE IT'S TOO LATE: One of the world's biggest infrastructure projects is racing ahead, despite court orders to halt construction. Conservationists fear that a train line looping around the Yucatan Peninsula is going to wreak havoc on the fragile Mexican cenotes, the jungle above and the coral reefs that border the coast
- Author
-
Russell, Mark
- Subjects
Fresh water ,Aquifers ,Infrastructure (Economics) ,Coral reefs and islands ,Courts -- Mexico ,Archaeology ,Environmentalists ,Geography - Abstract
On 19 June this year, Mexico's First District Court issued an order to halt construction on Section 5 South of Tren Maya--the Mayan Train. It's at least the sixth time [...]
- Published
- 2024
4. BELOW THE LINE: One of the world's natural wonders is being extensively damaged by the construction of a railway line
- Author
-
Russell, Mark 'Crowley'
- Subjects
Fresh water ,Aquifers ,Railroads -- Design and construction - Abstract
In December 2019, a referendum overwhelmingly approved the construction of a 1,554-kilometre railway through the jungles of Mexico's Yucatan peninsula, the 120km southern section of which--Section 5--would pass directly over [...]
- Published
- 2024
5. Abstract 4147845: Valsartan and Cardiac Remodeling in Early-Stage Hypertrophic Cardiomyopathy: The VANISH Trial Cardiac Magnetic Resonance Substudy
- Author
-
Ostrominski, John, Claggett, Brian, Jerosch-Herold, Michael, Axelsson, Anna, Day, Sharlene, Russell, Mark, Zahka, Kenneth, Pereira, Alexandre, Colan, Steven, Murphy, Anne, Canter, Charles, Bach, Richard, Wheeler, Matthew, Rossano, Joseph, Owens, Anjali, Mestroni, Luisa, Taylor, Matthew, Patel, Amit, Wilmot, Ivan, Soslow, Jonathan, Becker, Jason, Lakdawala, Neal, Bundgaard, Henning, Vargas, Jose, and Ho, Carolyn
- Published
- 2024
- Full Text
- View/download PDF
6. Long-Term Outcomes After Septal Reduction Therapies in Obstructive Hypertrophic Cardiomyopathy: Insights From the SHARE Registry
- Author
-
Maurizi, Niccolò, Antiochos, Panagiotis, Owens, Anjali, Lakdwala, Neal, Saberi, Sara, Russell, Mark W., Fumagalli, Carlo, Skalidis, Ioannis, Lin, Kimberly Y., Nathan, Ashwin S., De Feria Alsina, Alejandro, Reza, Nosheen, Stendahl, John C., Abrams, Dominic, Semsarian, Christopher, Clagget, Brian, Lampert, Rachel, Wheeler, Matthew, Parikh, Victoria N., Ashley, Euan, Michels, Michelle, Rossano, Joseph, Ryan, Thomas D., Ingles, Jodie, Ware, James, Ho, Carolyn Y., Helms, Adam S., Day, Sharlene M., and Olivotto, Iacopo
- Published
- 2024
- Full Text
- View/download PDF
7. Working together: Mark 'Crowley' Russell reports on a shark programme which combines science, conservation and tourism
- Author
-
Russell, Mark 'Crowley'
- Subjects
Travel industry -- Protection and preservation - Abstract
Each year between November and March, hundreds of bull sharks gather in the shallow coastal waters of Cozumel and Playa del Carmen on the Yucatan Peninsula, Mexico. Also arriving is [...]
- Published
- 2024
8. Apocrine Hidrocystoma of the Nail: A Unique Case
- Author
-
Salah, Haneen, Duran, Juanita, Russell, Mark A., and Gru, Alejandro A.
- Published
- 2024
- Full Text
- View/download PDF
9. Caffeine Gum Improves Reaction Time but Reduces Composure Versus Placebo During the Extra-Time Period of Simulated Soccer Match-Play in Male Semiprofessional Players.
- Author
-
Field, Adam, Corr, Liam, Birdsey, Laurence, Langley, Christina, Marshall, Ben, Wood, Greg, Hearris, Mark, Martinho, Diogo, Carbry, Christa, Naughton, Robert, Fleming, James, Mohr, Magni, Krustrup, Peter, Russell, Mark, and David Harper, Liam
- Subjects
BLOOD sugar analysis ,CAFFEINE ,REPEATED measures design ,STATISTICAL models ,SOCCER ,FOOD consumption ,EXERCISE ,T-test (Statistics) ,SENSORY perception ,STATISTICAL sampling ,BLIND experiment ,NEUROPHYSIOLOGY ,BLOOD collection ,HEMOGLOBINS ,RANDOMIZED controlled trials ,PSYCHOLOGICAL adaptation ,NEUROMUSCULAR system ,BLOOD volume determination ,OSMOLAR concentration ,DESCRIPTIVE statistics ,CHEWING gum ,VIRTUAL reality ,CROSSOVER trials ,HEART beat ,ANALYSIS of variance ,DIARY (Literary form) ,LACTATES ,HEMATOCRIT ,BLOOD plasma ,REACTION time ,BODY movement ,DIETARY carbohydrates ,BLOOD volume ,DATA analysis software ,CONFIDENCE intervals ,ERGOGENIC aids ,COGNITION ,SELF-perception ,SPRINTING ,MOTION capture (Human mechanics) ,PHARMACODYNAMICS - Abstract
This study aimed to determine whether caffeine gum influenced perceptual-cognitive and physical performance during the extra-time period of simulated soccer match-play. Semiprofessional male soccer players (n = 12, age: 22 ± 3 years, stature: 1.78 ± 0.06 m, mass: 75 ± 9 kg) performed 120-min soccer-specific exercise on two occasions. In a triple-blind, randomized, crossover design, players chewed caffeinated (200 mg; caffeine) or control (0 mg; placebo) gum for 5 min following 90 min of soccer-specific exercise. Perceptual-cognitive skills (i.e., passing accuracy, reaction time, composure, and adaptability) were assessed using a soccer-specific virtual reality simulator, collected pre- and posttrial. Neuromuscular performance (reactive-strength index, vertical jump height, absolute and relative peak power output, and negative vertical displacement) and sprint performance (15 and 30 m) were measured at pretrial, half-time, 90 min, and posttrial. Caffeine gum attenuated declines in reaction time (pre: 90.8 ± 0.8 AU to post: 90.7 ± 0.8 AU) by a further 4.2% than placebo (pre: 92.1 ± 0.8 AU to post: 88.2 ± 0.8 AU; p <.01). Caffeine gum reduced composure by 4.7% (pre: 69.1 ± 0.8 AU to post: 65.9 ± 0.8 AU) versus placebo (pre: 68.8 ± 0.8 AU to post: 68.3 ± 0.8 AU; p <.01). Caffeine gum did not influence any other variables (p >.05). Where caffeine gum is consumed by players prior to extra-time, reaction time increases but composure may be compromised, and neuromuscular and sprint performance remain unchanged. Future work should assess caffeine gum mixes with substances like L-theanine that promote a relaxed state under stressful conditions. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
10. The safety of antivirals and neutralising monoclonal antibodies used in prehospital treatment of Covid-19
- Author
-
Bechman, Katie, Green, Amelia CA, Russell, Mark D., Yang, Zijing, Zheng, Bang, Norton, Sam, Smith, Rebecca M., Mehrkar, Amir, Bacon, Sebastian C J, Goldacre, Ben, MacKenna, Brian, and Galloway, James B
- Published
- 2024
- Full Text
- View/download PDF
11. Identifying novel data-driven subgroups in congenital heart disease using multi-modal measures of brain structure
- Author
-
Vandewouw, Marlee M., Norris-Brilliant, Ami, Rahman, Anum, Assimopoulos, Stephania, Morton, Sarah U., Kushki, Azadeh, Cunningham, Sean, King, Eileen, Goldmuntz, Elizabeth, Miller, Thomas A., Thomas, Nina H., Adams, Heather R., Cleveland, John, Cnota, James F., Ellen Grant, P, Goldberg, Caren S., Huang, Hao, Li, Jennifer S., McQuillen, Patrick, Porter, George A., Roberts, Amy E., Russell, Mark W., Seidman, Christine E., Tivarus, Madalina E., Chung, Wendy K., Hagler, Donald J., Newburger, Jane W., Panigrahy, Ashok, Lerch, Jason P, Gelb, Bruce D., and Anagnostou, Evdokia
- Published
- 2024
- Full Text
- View/download PDF
12. Nitrogen narcosis--beware of the rapture of the deep: Mark 'Crowley' Russell warns that all too often, divers are unaware of the impact of nitrogen narcosis until it is too late
- Author
-
Russell, Mark 'Crowley'
- Abstract
* Back in my days as a full-time instructor, I was conducting the 40m dive of a Deep Diver speciality course when one of my students started indicating that there [...]
- Published
- 2024
13. The test–retest reliability and validity of food photography and food diary analyses.
- Author
-
Curtis, Christopher, Hills, Samuel P., Arjomandkhah, Nicola, Cooke, Carlton, Ranchordas, Mayur K., and Russell, Mark
- Subjects
FOOD consumption ,DATA analysis ,T-test (Statistics) ,BLIND experiment ,RESEARCH evaluation ,PHOTOGRAPHY ,NUTRITIONAL requirements ,DESCRIPTIVE statistics ,DIETARY fats ,FOOD ,FOOD labeling ,RESEARCH methodology ,STATISTICAL reliability ,STATISTICS ,INTRACLASS correlation ,FOOD diaries ,COMPARATIVE studies ,DATA analysis software ,DIETARY carbohydrates ,DIETARY proteins - Abstract
Aims: To assess test–retest reliability of both food photography and food diary methods and validity of these data against known values derived from food labels. Methods: Test–retest reliability analyses of food diary and food photography were compared using single foodstuffs using intra‐class correlation coefficients, coefficients of variation, and limits of agreement. For food diaries, 24‐h test–retest reliability was also examined. Validity was assessed against weighed analyses. As part of habitual intake, a single foodstuff (randomly allocated from 14 common foods) was consumed by 26 participants over 24‐h. On two occasions (14 days apart), single‐blind dietary analyses allowed estimation of foodstuff‐specific energy and macronutrient content and 24‐h intakes. Results: For food diaries, test–retest reliability was acceptable (weight, energy, carbohydrate, protein, and fat: all intra‐class correlation coefficients: >0.990, coefficient of variation percentage: <0.1%, limits of agreements: <0.1 to <0.1, p > 0.05, and effect size: <0.01). For food photography, test–retest reliability was acceptable for weight, energy, carbohydrate, and protein (all intra‐class correlation coefficients: >0.898, coefficient of variation percentage: 3.6%–6.2%, limits of agreements: 1.1 to – 44.9, and effect size: 0.01–0.12). Food photography validity was worse than food diaries for all variables (percentage difference: 8.8%–15.3%, coefficient of variation percentage: 7.5%–13.8%, all p ≤ 0.05, and effect size: 0.001–0.11). Conclusions: Greater reliability and validity occurred in food diaries versus food photography. These findings suggest that using food photography may lead to an underestimation of energy and macronutrient content, which may have implications for dietary interventions and nutritional strategies. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
14. 'Supporting the Support Staff': A Narrative Review of Nutritional Opportunities to Enhance Recovery and Wellbeing in Multi-Disciplinary Soccer Performance Staff.
- Author
-
Curtis, Christopher, Carling, Christopher, Tooley, Edward, and Russell, Mark
- Abstract
Background: With ever-increasing training, match-play and travel demands in professional soccer, recovery is vital for athletic performance, a statement amplified in tournament and in-season scenarios. However, alongside supporting the tasks associated with these increased demands, the recovery and wellbeing strategies recommended for playing staff are often unavailable to their support staff counterparts, who routinely experience extended working hours over and above scheduled player attendance. Methods: Focusing on the contributions of nutrition to this undoubtedly multifactorial issue, this narrative review aimed to (1) identify potential strategies to enhance recovery and wellbeing in multi-disciplinary soccer support staff and (2) highlight future research opportunities exploring the benefits of nutrition for those staff in soccer performance-related support roles. Results: The potential health and wellbeing consequences of chronic sub-optimal practices suggest that chrononutrition strategies may be an area of future interest. Notably, nutritional strategies that enhance sleep hygiene and immune function warrant consideration. Individualizing such strategies to maximize recovery and wellbeing in multi-disciplinary soccer support staff should offer an adjunct and complementary strategy to the holistic performance-focused support provided to professional soccer players. Conclusions: Policymakers responsible for organizational and club structures aligned with soccer performance could consider 'Supporting the Support Staff' when seeking to improve overall performance. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
15. Pneumococcal vaccine uptake in patients with inflammatory arthritis: a single centre cohort study
- Author
-
Nagra, Deepak, primary, Bechman, Katie, additional, Russell, Mark D, additional, Yang, Zijing, additional, Adas, Maryam A, additional, Molbanti, Hemanth, additional, Khan, Asim, additional, Wincup, Chris, additional, Alveyn, Edward, additional, Baldwin, Christopher, additional, Rutherford, Andrew I, additional, Subesinghe, Sujith, additional, Cope, Andrew, additional, and Galloway, James B, additional
- Published
- 2024
- Full Text
- View/download PDF
16. OA06 Regional differences in work productivity in patients with early rheumatoid arthritis in England and Wales
- Author
-
Alveyn, Edward, primary, Adas, Maryam, additional, Sahbudin, Ilfita, additional, Boonen, Annelies, additional, Bechman, Katie, additional, Russell, Mark D, additional, Nagra, Deepak, additional, Gallagher, Sarah, additional, Price, Elizabeth, additional, Walker-Bone, Karen, additional, Norton, Sam, additional, and Galloway, James, additional
- Published
- 2024
- Full Text
- View/download PDF
17. P086 Trends in the Incidence and Management of Gout in England: A Nationwide Study using the OpenSAFELY Platform
- Author
-
Russell, Mark D, primary, Massey, Jon, additional, Roddy, Edward, additional, MacKenna, Brian, additional, Bacon, Seb, additional, Goldacre, Ben, additional, Andrews, Colm D, additional, Hickman, George, additional, Mehrkar, Amir, additional, Mahto, Arti, additional, Rutherford, Andrew I, additional, Patel, Samir, additional, Adas, Maryam A, additional, Alveyn, Edward, additional, Nagra, Deepak, additional, Bechman, Katie, additional, Ledingham, Jo M, additional, Hudson, Joanna, additional, Norton, Sam, additional, Cope, Andrew, additional, and Galloway, James, additional
- Published
- 2024
- Full Text
- View/download PDF
18. P039 A systematic review and meta analysis of anti rheumatic drugs and pneumococcal vaccine immunogenicity in inflammatory arthritis
- Author
-
Nagra, Deepak, primary, Bechman, Katie, additional, Adas, Maryam, additional, Yang, Zijing, additional, Alveyn, Edward, additional, Patel, Samir, additional, Russell, Mark, additional, Norton, Sam, additional, Wincup, Chris, additional, Baldwin, Christopher, additional, and Galloway, James, additional
- Published
- 2024
- Full Text
- View/download PDF
19. OA39 The influence of safety warnings on the prescribing of JAK inhibitors in England: an interrupted time-series analysis
- Author
-
Russell, Mark D, primary, Yang, Zijing, additional, Walter, Ben, additional, Alveyn, Edward, additional, Bechman, Katie, additional, Miracle, Aitana, additional, Nagra, Deepak, additional, Adas, Maryam A, additional, and Galloway, James B, additional
- Published
- 2024
- Full Text
- View/download PDF
20. OA20 Serious infections hospital admissions and mortality in patients with early inflammatory arthritis: results from the National Early Inflammatory Arthritis Audit
- Author
-
Adas, Maryam, primary, Bechman, Katie, additional, Russell, Mark, additional, Karafotias, Ioasaf, additional, Nagra, Deepak, additional, Patel, Samir, additional, Gallagher, Sarah, additional, Price, Elizabeth, additional, Garton, Mark, additional, Rutherford, Andrew, additional, Cope, Andrew, additional, Norton, Sam, additional, and Galloway, James, additional
- Published
- 2024
- Full Text
- View/download PDF
21. Regulation of STAT1 Signaling in Human Pancreatic β-Cells by the Lysine Deacetylase HDAC6: A New Therapeutic Opportunity in Type 1 Diabetes?
- Author
-
Leslie, Kaiyven Afi, Lekka, Christiana, Richardson, Sarah J., Russell, Mark A., and Morgan, Noel G.
- Subjects
TYPE 1 diabetes ,STAT proteins ,ISLANDS of Langerhans ,GENETIC transcription ,PHOSPHORYLATION - Abstract
Type 1 diabetes arises from the selective destruction of pancreatic β-cells by autoimmune mechanisms, and intracellular pathways driven by Janus kinase (JAK)–mediated phosphorylation of STAT isoforms (especially STAT1 and STAT2) are implicated as mediators of β-cell demise. Despite this, the molecular mechanisms that regulate JAK-STAT signaling in β-cells during the autoimmune attack remain only partially disclosed, and the factors acting to antagonize proinflammatory STAT1 signaling are uncertain. We have recently implicated signal regulatory protein α (SIRPα) in promoting β-cell viability in the face of ongoing islet autoimmunity and have now revealed that this protein controls the availability of a cytosolic lysine deacetylase, HDAC6, whose activity regulates the phosphorylation and activation of STAT1. We provide evidence that STAT1 serves as a substrate for HDAC6 in β-cells and that sequestration of HDAC6 by SIRPα in response to anti-inflammatory cytokines (e.g., IL-13) leads to increased STAT1 acetylation. This then impairs the ability of STAT1 to promote gene transcription in response to proinflammatory cytokines, including interferon-γ. We further found that SIRPα is lost from the β-cells of subjects with recent-onset type 1 diabetes under conditions when HDAC6 is retained and STAT1 levels are increased. On this basis, we report a previously unrecognized role for cytokine-induced regulation of STAT1 acetylation in the control of β-cell viability and propose that targeted inhibition of HDAC6 activity may represent a novel therapeutic modality to promote β-cell viability in the face of active islet autoimmunity. Article Highlights: Signal regulatory protein α (SIRPα) is present in human islet cells, but its levels decline in β-cells in type 1 diabetes. Decreases in SIRPα expression are associated with a reduction in the viability of cultured β-cells. Immunoprecipitation of β-cell SIRPα reveals a direct interaction with the lysine deacetylase HDAC6. Sequestration of HDAC6 by SIRPα results in increased acetylation, reduced phosphorylation, and impaired activation of STAT1 during exposure of β-cells to interferon-γ. Pharmacological targeting of HDAC6 might yield improvements in β-cell viability during progression to type 1 diabetes. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
22. The Impact of Extracellular Histones and Absence of Toll-like Receptors on Cardiac Functional and Electrical Disturbances in Mouse Hearts.
- Author
-
Loaiza, Randall, Fattahi, Fatemeh, Kalbitz, Miriam, Grailer, Jamison J., Russell, Mark W., Jalife, Jose, Valdivia, Hector H., Zetoune, Firas S., and Ward, Peter A.
- Subjects
HEART diseases ,HISTONES ,TOLL-like receptors ,INTRAVENOUS injections ,ARRHYTHMIA - Abstract
In polymicrobial sepsis, the extracellular histones, mainly released from activated neutrophils, significantly contribute to cardiac dysfunction (septic cardiomyopathy), as demonstrated in our previous studies using Echo-Doppler measurements. This study aims to elucidate the roles of extracellular histones and their interactions with Toll-like receptors (TLRs) in cardiac dysfunction. Through ex vivo assessments of ECG, left ventricle (LV) function parameters, and in vivo Echo-Doppler studies in mice perfused with extracellular histones, we aim to provide comprehensive insights into the mechanisms underlying sepsis-induced cardiac dysfunction. Langendorff-perfused hearts from both wild-type and TLR2, TLR3, or TLR4 knockout (KO) mice were examined. Paced mouse hearts were perfused with histones to assess contractility and relaxation. Echo-Doppler studies evaluated cardiac dysfunction after intravenous histone injection. Histone perfusion caused defects in contractility and relaxation, with TLR2 and TLR3 KO mice being partially protected. Specifically, TLR2 KO mice exhibited the greatest reduction in Echo-Doppler abnormalities, while TLR4 KO exacerbated cardiac dysfunction. Among individual histones, H1 induced the most pronounced abnormalities in cardiac function, apoptosis of cardiomyocytes, and LDH release. Our data highlight significant interactions between histones and TLRs, providing insights into histones especially H1 as potential therapeutic targets for septic cardiomyopathy. Further studies are needed to explore specific histone–TLR interactions and their mechanisms. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
23. Implementing treat-to-target urate-lowering therapy during hospitalizations for gout flares.
- Author
-
Russell, Mark D, Ameyaw-Kyeremeh, Louise, Dell'Accio, Flora, Lapham, Heather, Head, Natalie, Stovin, Christopher, Patel, Vishit, Clarke, Benjamin D, Nagra, Deepak, Alveyn, Edward, Adas, Maryam A, Bechman, Katie, Puente, María A de la, Ellis, Benjamin, Byrne, Corrine, Patel, Rina, Rutherford, Andrew I, Cantle, Fleur, Norton, Sam, and Roddy, Edward
- Subjects
- *
HUMAN services programs , *NURSE administrators , *OUTPATIENT medical care management , *T-test (Statistics) , *CRONBACH'S alpha , *RESEARCH funding , *HOSPITAL care , *PRIMARY health care , *PATIENT readmissions , *SEX distribution , *MEDICAL care , *LOGISTIC regression analysis , *NURSING interventions , *TREATMENT effectiveness , *RETROSPECTIVE studies , *DESCRIPTIVE statistics , *AGE distribution , *DISCHARGE planning , *CHI-squared test , *GOUT suppressants , *LONGITUDINAL method , *PRE-tests & post-tests , *ODDS ratio , *KAPLAN-Meier estimator , *GOUT , *URIC acid , *ALLOPURINOL , *MEDICAL records , *ACQUISITION of data , *COMPARATIVE studies , *CONFIDENCE intervals , *JOINT diseases , *STAKEHOLDER analysis , *DATA analysis software , *PATIENT aftercare , *TIME , *REGRESSION analysis - Abstract
Objectives To evaluate a strategy designed to optimize care and increase uptake of urate-lowering therapy (ULT) during hospitalizations for gout flares. Methods We conducted a prospective cohort study to evaluate a strategy that combined optimal in-hospital gout management with a nurse-led, follow-up appointment, followed by handover to primary care. Outcomes, including ULT initiation, urate target attainment and re-hospitalization rates, were compared between patients hospitalized for flares in the 12 months post-implementation and a retrospective cohort of hospitalized patients from 12 months pre-implementation. Results One hundred and nineteen and 108 patients, respectively, were hospitalized for gout flares in the 12 months pre- and post-implementation. For patients with 6-month follow-up data available (n = 94 and n = 97, respectively), the proportion newly initiated on ULT increased from 49.2% pre-implementation to 92.3% post-implementation (age/sex-adjusted odds ratio [aOR] 11.5; 95% CI 4.36, 30.5; P < 0.001). After implementation, more patients achieved a serum urate ≤360 μmol/l within 6 months of discharge (10.6% pre-implementation vs 26.8% post-implementation; aOR 3.04; 95% CI 1.36, 6.78; P = 0.007). The proportion of patients re-hospitalized for flares was 14.9% pre-implementation vs 9.3% post-implementation (aOR 0.53; 95% CI 0.22, 1.32; P = 0.18). Conclusion Over 90% of patients were initiated on ULT after implementing a strategy to optimize hospital gout care. Despite increased initiation of ULT during flares, recurrent hospitalizations were not more frequent following implementation. Significant relative improvements in urate target attainment were observed post-implementation; however, for the majority of hospitalized gout patients to achieve urate targets, closer primary–secondary care integration is still needed. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
24. Quality of Life and Exercise Capacity in Early Stage and Subclinical Hypertrophic Cardiomyopathy: A Secondary Analysis of the VANISH Trial.
- Author
-
Ireland, Catherine G., Burstein, Danielle S., Day, Sharlene M., Raja, Anna Axelsson, Russell, Mark W., Zahka, Kenneth G., Pereira, Alexandre, Canter, Charles E., Bach, Richard G., Wheeler, Matthew T., Rossano, Joseph W., Owens, Anjali T., Bundgaard, Henning, Mestroni, Luisa, Taylor, Matthew R. G., Patel, Amit R., Wilmot, Ivan, Soslow, Jonathan H., Becker, Jason R., and Giverts, Ilya
- Abstract
BACKGROUND: The health-related quality of life (HRQOL) and cardiopulmonary exercise testing (CPET) performance of individuals with subclinical and early stage hypertrophic cardiomyopathy (HCM) have not been systematically studied. Improved understanding will inform the natural history of HCM and factors influencing well-being. METHODS: VANISH trial (Valsartan for Attenuating Disease Evolution in Early Sarcomeric HCM) participants with early stage sarcomeric HCM (primary analysis cohort) and subclinical HCM (sarcomere variant without left ventricular hypertrophy comprising the exploratory cohort) who completed baseline and year 2 HRQOL assessment via the pediatric quality of life inventory and CPET were studied. Metrics correlating with baseline HRQOL and CPET performance were identified. The impact of valsartan treatment on these measures was analyzed in the early stage cohort. RESULTS: Two hundred participants were included: 166 with early stage HCM (mean age, 23±10 years; 40% female; 97% White; and 92% New York Heart Association class I) and 34 subclinical sarcomere variant carriers (mean age, 16±5 years; 50% female; and 100% White). Baseline HRQOL was good in both cohorts, although slightly better in subclinical HCM (composite pediatric quality of life score 84.6±10.6 versus 90.2±9.8; P=0.005). Both cohorts demonstrated mildly reduced functional status (mean percent predicted peak oxygen uptake 73±16 versus 78±12 mL/kg per minute; P=0.18). Percent predicted peak oxygen uptake and peak oxygen pulse correlated with HRQOL. Valsartan improved physical HRQOL in early stage HCM (adjusted mean change in pediatric quality of life score +4.1 versus placebo; P=0.01) but did not significantly impact CPET performance. CONCLUSIONS: Functional capacity can be impaired in young, healthy people with early stage HCM, despite New York Heart Association class I status and good HRQOL. Peak oxygen uptake was similarly decreased in subclinical HCM despite normal left ventricular wall thickness and excellent HRQOL. Valsartan improved physical pediatric quality of life scores but did not significantly impact CPET performance. Further studies are needed for validation and to understand how to improve patient experience. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
25. Occupational impacts of early inflammatory arthritis: results from the National Early Inflammatory Arthritis Audit.
- Author
-
Bechman, Katie, Cook, Emma S, Alveyn, Edward, Houssien, Abdullah, Stevens, Martin, Russell, Mark D, Adas, Maryam, Amlani-Hatcher, Paul, Norton, Sam, Lempp, Heidi, Ledingham, Joanna M, Galloway, James B, and Walker-Bone, Karen
- Subjects
AUDITING ,JOB absenteeism ,RESEARCH funding ,RHEUMATOID arthritis ,DESCRIPTIVE statistics ,LONGITUDINAL method ,RESEARCH methodology ,SOCIODEMOGRAPHIC factors ,EMPLOYMENT ,REGRESSION analysis ,DISEASE complications - Abstract
Objectives Inflammatory arthritis causes significant work disability. Studies regarding this frequently fail to report important contextual information such as employment type. Our objective was to explore work participation, by gender and occupation type, in early inflammatory arthritis. Methods Data are from the National Early Inflammatory Arthritis Audit for 2018–2020. At diagnosis, clinicians collected information on demographics, inflammatory arthritis disease activity, and working status. Participants completed patient-reported outcomes at baseline, 3 months and 12 months, including occupation and Work Productivity and Activity Impairment (WPAI). Descriptive analyses of work participation and WPAI scores by occupational class at all time points were performed. Regression models were used to examine associations between WPAI score and occupation. Results In all, 12 473 people received a diagnosis of inflammatory arthritis and reported employment status, among whom 5999 (47%) were in paid work for at least 20 hours/week. At diagnosis, the working cohort had statistically significant lower measures of disease activity (P < 0.001). Occupational data were available for 3694 individuals. At diagnosis, 2793 completed a WPAI; 200 (7.2%) had stopped work and 344 (12.3%) changed jobs because of inflammatory arthritis symptoms. There was a high burden of absenteeism (30%) and presenteeism (40%). Compared with managerial or professional workers, the burden of work disability was greater among those in routine (manual) occupations. During follow-up, 9.4% of WPAI completers stopped work and 14.6% changed roles. Work drop-out occurred almost entirely among people doing routine jobs. Conclusion It is easier to retain work in certain employment sectors. Participation in routine jobs is more affected, which may widen health inequalities. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
26. The silent struggle of asylum-seeking children
- Author
-
Russell, Mark, primary
- Published
- 2024
- Full Text
- View/download PDF
27. The influence of safety warnings on the prescribing of JAK inhibitors
- Author
-
Russell, Mark D, primary, Yang, Zijing, additional, Walter, Ben, additional, Alveyn, Edward, additional, Bechman, Katie, additional, Miracle, Aitana, additional, Nagra, Deepak, additional, Adas, Maryam A, additional, Norton, Sam, additional, Cope, Andrew P, additional, Langan, Sinéad M, additional, and Galloway, James B, additional
- Published
- 2024
- Full Text
- View/download PDF
28. No Waning of Pneumococcal Vaccine Responses over Time in People with Inflammatory Arthritis: Findings from a Single Centre Cohort
- Author
-
Nagra, Deepak, primary, Bechman, Katie, additional, Russell, Mark D., additional, Yang, Zijing, additional, Adas, Maryam, additional, Subesinghe, Sujith, additional, Rutherford, Andrew, additional, Alveyn, Edward, additional, Patel, Samir, additional, Wincup, Chris, additional, Mahto, Arti, additional, Baldwin, Christopher, additional, Karafotias, Ioasaf, additional, Cope, Andrew, additional, Norton, Sam, additional, and Galloway, James, additional
- Published
- 2024
- Full Text
- View/download PDF
29. Trust performance in managing inflammatory arthritis over time in England and Wales: a latent class analysis approach.
- Author
-
Yang, Zijing, Arumalla, Nikita, Alveyn, Edward, Gallagher, Sarah, Price, Elizabeth, Russell, Mark D, Bechman, Katie, Norton, Sam, and Galloway, James
- Subjects
TREATMENT of arthritis ,RHEUMATISM ,RHEUMATOLOGY - Abstract
Objectives To evaluate trust-level performance in time to initiation of DMARD therapy in patients with early inflammatory arthritis (EIA), with identification of the change in performance trajectories over time and investigation of trust characteristics associated with this change. Methods We included 130 trusts from the UK contributing to the National Early Inflammatory Arthritis Audit (NEIAA) from 2018 to 2020. The primary outcome was days from referral to initiation of DMARD therapy in patients with EIA. Latent class growth mixture models were applied to identify distinct groups of trusts with similar trajectories of performance change over time. We used mixed effects linear and multinomial logistic regression models to evaluate the association between delay in treatment and trust-level characteristics. Results The mean time to DMARD initiation was 53 days (s. d. 18), with an average 0.3-day decrease with each month over time. Four latent trajectories were identified in our cohort, with >77% of individual trusts showing ongoing improvements in decreasing treatment waiting times. Prior to separating by latent class, time to DMARD initiation was shorter in trusts with higher rheumatology staffing, a local EIA treatment pathway and those with access to musculoskeletal ultrasound. Trusts with more nurses in the rheumatology department were less likely to be in the worst performance group [odds ratio 0.69 (95% CI 0.49, 0.93)]. Conclusion In this cohort study, we observed a reduction in treatment waiting time over time. Trusts with better staffed and improved EIA clinical structure are likely to initiate definitive treatment earlier in patients with EIA. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
30. Incidence of Uveitis in Patients With Axial Spondylarthritis Treated With Biologics or Targeted Synthetics: A Systematic Review and Network Meta‐Analysis.
- Author
-
Bechman, Katie, Yang, Zijing, Adas, Maryam, Nagra, Deepak, S. Uğuzlar, Ali, Russell, Mark D., Wilson, Nicky, Steer, Sophia, Norton, Sam, and Galloway, James
- Subjects
BIOTHERAPY ,UVEITIS ,RISK assessment ,MEDICAL information storage & retrieval systems ,ANKYLOSIS ,BIOLOGICAL products ,META-analysis ,DESCRIPTIVE statistics ,SYSTEMATIC reviews ,MEDLINE ,SPONDYLOARTHROPATHIES ,SYNTHETIC drugs ,COMPARATIVE studies ,CONFIDENCE intervals ,DISEASE risk factors - Abstract
Objective: Anterior uveitis is a common extra‐articular manifestation of axial spondyloarthritis (AxSpA). We set to evaluate the risk of anterior uveitis (AU) with biologics and synthetic disease‐modifying drugs in AxSpA. Methods: We conducted a systematic review and meta‐analysis to identify phase II/III double‐blinded randomized controlled trials of anti–tumor necrosis factor (TNF) monoclonal antibodies (mAb), anti–interleukin‐17 (anti–IL‐17), and Janus kinase inhibitors (JAKi) in AxSpA. Patient‐exposure years (PEY) were calculated using the per‐protocol approach. Incidence rate (IR) of AU/100 person‐years were calculated by treatment group using the random effects approach. Network meta‐analysis (NMA) was used to estimate risk of AU in treatment groups, expressed as IR ratios (IRRs). Bias was assessed using the Cochrane Risk of Bias‐2 tool. Results: Forty‐four trials were included: 17 anti‐TNF mAb (1,004 PEY), 9 etanercept (180 PEY), 13 anti–IL‐17 (1,834 PEY), and 6 JAKi (331 PEY). The IR of AU were as follows for anti‐TNF mAb: 4.1, 95% confidence interval (CI) 0–8.5; etanercept: 5.4, 95% CI 0–16.0; anti–IL‐17: 2.8, 95% CI 1.6–4.1; JAKi: 1.5, 95% CI 0.0–3.0; and placebo: 10.8, 95% CI 7.4–14.1. In NMA, IRRs of treatments compared with placebo were as follows for anti‐TNF mAb: 0.32, 95% CI 0.10–1.04; etanercept 0.42, 95% CI 0.08–2.38; anti–IL‐17: 0.43, 95% CI 0.19–0.98; and JAKi: 0.32, 95% CI 0.06–1.67. Comparisons between anti‐TNF mAb, anti–IL‐17, and JAKi did not demonstrate any significant difference in AU risk. Using the surface under the cumulative ranking curve approach to rank AU risk, anti‐TNF mAbs were associated with the lowest risk followed by JAKi, anti–IL‐17, and etanercept. All treatments were ranked superior to placebo. Conclusion: Anti‐TNF mAbs, JAKi, and anti–IL‐17 appear protective against AU events in individuals with AxSpA, with no significant differences in risk of AU between treatments. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
31. Driving down the cost of biologics: lessons from a nationalised health-care system.
- Author
-
Russell, Mark D and Galloway, James B
- Subjects
- *
HEALTH care industry , *BIOLOGICALS , *COST - Published
- 2024
- Full Text
- View/download PDF
32. PREDICTORS OF ADVERSE LONG-TERM OUTCOME AFTER SEPTAL REDUCTION THERAPIES IN OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY : INSIGHTS FROM THE SHARE REGISTRY
- Author
-
Maurizi, Niccolo’, Antiochos, Panagiotis, Owens, Anjali Tiku, Lakdawala, Neal K., Saberi, Sara, Russell, Mark W., Lin, Kimberly Y., De Feria Alsina, Alejandro, Reza, Nosheen, Stendahl, John, Abrams, Dominic J., Semsarian, Christopher, Lampert, Rachel J., Parikh, Victoria, Wheeler, Matthew Thomas, Ashley, Euan A., Michels, Michelle, Rossano, Joseph William, Ryan, Thomas D., Ingles, Jodie, Ware, James, Ho, Carolyn, Helms, Adam, Day, Sharlene M., and Olivotto, Iacopo
- Published
- 2024
- Full Text
- View/download PDF
33. Patient Characteristics and Burden of Disease in Adults with MYBPC3-Associated Hypertrophic Cardiomyopathy (MYBPC3+ HCM): Insights from the SHaRe Registry.
- Author
-
Wang, Whedy, Varfaj, Bardha, Robertson, Laura, Harrison, Will, Haroldson, Jeff, Tingley, Whitmore, Lakdawala, Neal, Owens, Anjali, Saberi, Sara, Lin, Kim, Stendhal, John, Parikh, Vicki, Ingles, Jodie, Ashley, Euan, Ware, James, Michels, Michelle, Lampert, Rachel, Abrams, Dominic, Rossano, Joe, and Russell, Mark
- Abstract
Pathogenic variants in the MYBPC3 gene are the leading genetic cause of hypertrophic cardiomyopathy (HCM) resulting in reduced functional myosin-binding protein C (MyBP-C) levels. Studies have shown that adult patients with pathogenic sarcomere variant-HCM exhibit higher incidence of major clinical events than genotype-negative HCM patients. With the emergence of gene replacement therapies, characterizing the natural history of MYBPC3 + HCM is essential to inform future development of this class of targeted therapies. We conducted an analysis of all adult MYBPC3 + HCM patients enrolled in SHaRe (Sarcomeric Human Cardiomyopathy Registry) based on their primary diagnosis at the age of 18-39, 40-59, and ≥60 years. As of September 2023, 1493 adult HCM patients with a pathogenic or likely pathogenic variant in MYBPC3 had enrolled in SHaRe, a multicenter registry involving 12 cardiac centers in the US, EU, and Australia. This analysis included 635 patients (42.5%) diagnosed at 18–39 years, 659 (44.1%) at 40–59 years, and 199 (13.3%) at ≥60 years. Duration of follow-up in the three cohorts was 8.4, 6.6, and 4.5 years, respectively. Demographics, genotype, first echocardiographic metrics, and time to major clinical events were compared across the three groups. Most patients diagnosed at 18–39 and 40–59 years were males (67.0% and 56.3% respectively), while those diagnosed at ≥60 years were primarily female (59.5%). Family history of HCM and proband status were comparable across cohorts (range of 56.3 – 65.7% and 88.0 – 91.5%, respectively). Patients in the youngest cohort presented with the greatest left ventricular maximal wall thickness (median of 19 mm, 18 mm, and 17 mm for the 18 – 39, 40 – 59, and ≥60 years cohorts, respectively). Symptom burden was comparable across cohorts, as the proportion of patients with NYHA III/IV was 13.1%, 10.5%, and 11.4%, respectively. The prevalence of patients having SRT, syncope and need for transplant or left ventricular assist device (LVAD) were highest in the youngest cohort (see Table). Across all three cohorts, patients experienced atrial fibrillation (AF) at 13.7%, the ventricular arrhythmia (VA) composite at 5.3%, and the heart failure (HF) composite at 9.1%. Adult MYBPC3 + HCM patients of all ages are at risk for serious clinical manifestations including heart failure, arrhythmias, and sudden cardiac death (SCD). These findings underscore the importance of genetic diagnosis and development of targeted therapies to restore MyBP-C levels, which could potentially modify the natural history of the disease. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
34. YOU ALSO SAID... UNIVERSAL TOWING MIRRORS.
- Author
-
Russell, Mark
- Subjects
MIRRORS ,TOWING - Abstract
The article discusses various topics related to caravanning and camping. One reader shares their experience with using wheel locks for added security on their seasonal pitch, while another reader praises the quality of EMUK towing mirrors for their BMW X3. The article also mentions a classic and vintage vehicle show in North Yorkshire that will introduce a Campervan and Caravan Corner in response to feedback from campervan owners. The exhibition will feature classic cars, motorcycles, and vintage campers and caravans, with ticket proceeds going to charity. [Extracted from the article]
- Published
- 2024
35. Increased Disease Severity and Compound Sarcomere Variant Burden in Pediatric-Onset Compared to Adult-Onset MYBPC3-Associated Hypertrophic Cardiomyopathy (MYBPC3+ HCM): Insights from the SHaRe Registry.
- Author
-
Meisner, Joshua, Varfaj, Bardha, Wang, Whedy, Haroldson, Jeff, Harrison, Will, Tingley, Whitmore, Lakdawala, Neal, Owens, Anjali, Saberi, Sara, Lin, Kim, Stendahl, John, Parikh, Vicki, Ingles, Jodie, Ashley, Euan, Ware, James, Michels, Michelle, Lampert, Rachel, Abrams, Dominic, Rossano, Joe, and Russell, Mark
- Abstract
Heterozygous MYBPC3 variants are the leading genetic cause of hypertrophic cardiomyopathy (HCM). Pathogenic and likely pathogenic (P/LP) MYBPC3 variants (MYBPC3 +) are predominantly truncating variants and result in reduced functional protein (MyBP-C) levels. Despite a common genetic basis, there is wide variability in disease severity and onset. Prior work demonstrates pediatric-onset HCM associated with sarcomeric mutations has worse outcomes, but limited studies have examined this by genotype. To better understand the natural history of pediatric-onset MYBPC3+ HCM, we analyzed data of all MYBPC3 + HCM patients enrolled in SHaRe (Sarcomeric Human Cardiomyopathy Registry). As of December 2023, 1,713 HCM patients with ≥1 P/LP MYBPC3 variants had been enrolled in SHaRe, a multicenter registry spanning 12 cardiac centers in the US, EU, and Australia. Pediatric-onset (218/1713 patients) and adult-onset MYBPC3 + HCM (1495/1713) were defined as <18 and ≥18 years of age, respectively. Both cohorts were followed for a similar median duration of 7 years. Analysis of demographics, genotype, first echocardiographic metrics, and time to major clinical events was performed and compared across pediatric and adult groups. Compound heterozygosity for MYBPC3 P/LP variants was more common in pediatric disease onset (8.3%) compared to adult-onset (3.7%) (p=0.002). Pediatric-onset MYBPC3 + HCM had more prominent hypertrophy with median left ventricular wall thickness (LVMWT) Z score 11.5 vs 8.9 in adult-onset disease (p=0.006). While the prevalence of overall composite events (i.e. death, transplant, heart failure, or ventricular arrhythmia events) was similar in pediatric- and adult-onset MYBPC3 + HCM patients (16.1% and 20.2%, respectively), events occurred 27 years earlier in the pediatric-onset cohort (median age at event 30.5 vs 57.5 years, p<0.001). Heart failure (HF) composite outcomes and septal reduction therapy (SRT) demonstrated a pattern of similar prevalence between pediatric- and adult-onset disease (HF: 11.5% pediatric and 9.1% adult; SRT: 11.5% pediatric and 13.2% adult) but with earlier onset (HF: median 23 years earlier; SRT: median 23 years earlier, p<0.001). Pediatric-onset MYBPC3+ HCM patients had more severe hypertrophy and showed an earlier age of disease morbidity than adult-onset MYBPC3+ HCM. These results underscore the critical importance of early clinical diagnosis with genetic confirmation to understand prognostic implications and guide treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
36. British Society of Rheumatology guideline working group response to European Medicines Agency safety update on Hydroxychloroquine.
- Author
-
Russell, Mark D, Dey, Mrinalini, Flint, Julia, Davie, Philippa, Allen, Alexander, Crossley, Amy, Frishman, Margreta, Gayed, Mary, Hodson, Kenneth, Khamashta, Munther, Moore, Louise, Panchal, Sonia, Piper, Madeleine, Reid, Clare, Saxby, Katherine, Schreiber, Karen, Senvar, Naz, Tosounidou, Sofia, van de Venne, Maud, and Warburton, Louise
- Subjects
- *
DRUG therapy for rheumatism , *CLEFT lip , *MORNING sickness , *VACCINES , *RHEUMATOLOGY , *PHARMACOLOGY , *ANTI-inflammatory agents , *HUMAN abnormalities , *CLEFT palate , *INFLIXIMAB , *ANTIRHEUMATIC agents , *MEDICAL protocols , *DISEASE relapse , *PRENATAL exposure delayed effects , *TEACHING aids , *ONDANSETRON , *DOSE-effect relationship in pharmacology , *HYDROXYCHLOROQUINE , *PATIENT safety , *DISEASE risk factors , *CHILDREN , *PREGNANCY , *FETUS ,RISK factors - Published
- 2024
- Full Text
- View/download PDF
37. New ministers must prioritise child welfare
- Author
-
Russell, Mark
- Published
- 2024
- Full Text
- View/download PDF
38. Next government must prioritise children
- Author
-
Russell, Mark
- Published
- 2024
- Full Text
- View/download PDF
39. OpenSAFELY: The impact of COVID‐19 on azathioprine, leflunomide and methotrexate monitoring, and factors associated with change in monitoring rate.
- Author
-
Brown, Andrew D., Fisher, Louis, Curtis, Helen J., Wiedemann, Milan, Hulme, William J., Speed, Victoria, Hopcroft, Lisa E. M., Cunningham, Christine, Costello, Ruth E., Galloway, James B., Russell, Mark D., Bechman, Katie, Kurt, Zeyneb, Croker, Richard, Wood, Chris, Walker, Alex J., Schaffer, Andrea L., Bacon, Seb C. J., Mehrkar, Amir, and Hickman, George
- Abstract
Aims Methods Results Conclusion The COVID‐19 pandemic created unprecedented pressure on healthcare services. This study investigates whether disease‐modifying antirheumatic drug (DMARD) safety monitoring was affected during the COVID‐19 pandemic.A population‐based cohort study was conducted using the OpenSAFELY platform to access electronic health record data from 24.2 million patients registered at general practices using TPP's SystmOne software. Patients were included for further analysis if prescribed azathioprine, leflunomide or methotrexate between November 2019 and July 2022. Outcomes were assessed as monthly trends and variation between various sociodemographic and clinical groups for adherence with standard safety monitoring recommendations.An acute increase in the rate of missed monitoring occurred across the study population (+12.4 percentage points) when lockdown measures were implemented in March 2020. This increase was more pronounced for some patient groups (70–79 year‐olds: +13.7 percentage points; females: +12.8 percentage points), regions (North West: +17.0 percentage points), medications (leflunomide: +20.7 percentage points) and monitoring tests (blood pressure: +24.5 percentage points). Missed monitoring rates decreased substantially for all groups by July 2022. Consistent differences were observed in overall missed monitoring rates between several groups throughout the study.DMARD monitoring rates temporarily deteriorated during the COVID‐19 pandemic. Deterioration coincided with the onset of lockdown measures, with monitoring rates recovering rapidly as lockdown measures were eased. Differences observed in monitoring rates between medications, tests, regions and patient groups highlight opportunities to tackle potential inequalities in the provision or uptake of monitoring services. Further research should evaluate the causes of the differences identified between groups. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
40. Low Penetrance Sarcomere Variants Contribute to Additive Risk in Hypertrophic Cardiomyopathy.
- Author
-
Meisner JK, Renberg A, Smith ED, Tsan YC, Elder B, Bullard A, Merritt O, Zheng SL, Lakdawala N, Owens A, Ryan TD, Miller EM, Rossano J, Lin KY, Claggett B, Ashley E, Michels M, Lampert R, Stendahl JC, Abrahams D, Semsarian C, Parikh VN, Wheeler M, Ingles J, Day SM, Saberi S, Russell MW, Previs M, Ho C, Ware JS, and Helms AS
- Abstract
Background: Classically, hypertrophic cardiomyopathy (HCM) has been viewed as a single-gene (monogenic) disease caused by pathogenic variants in sarcomere genes. Pathogenic sarcomere variants are individually rare and convey high risk for developing HCM (highly penetrant). Recently, important polygenic contributions have also been characterized. Low penetrance sarcomere variants (LowSVs) at intermediate frequencies and effect sizes have not been systematically investigated. We hypothesize that LowSVs may be common in HCM with substantial influence on disease risk and severity., Methods: Among all sarcomere variants observed in the Sarcomeric Human Cardiomyopathy Registry (SHaRe), we identified putative LowSVs defined by (1) population frequency greater than expected for highly penetrant (monogenic) HCM (allele frequency >5×10
-5 in the Genome Aggregation Database, gnomAD) and (2) moderate enrichment (>2×) in patients with HCM compared with gnomAD. LowSVs were examined for their association with disease severity and clinical outcomes. Functional effects of selected LowSVs were assessed using induced pluripotent stem cell-derived cardiomyocytes. Association of LowSVs with HCM-adjacent traits in the general population was tested using UK Biobank cardiac magnetic resonance imaging data., Results: Among 6045 patients and 1159 unique variants in sarcomere genes, 12 LowSVs were identified. LowSVs were collectively common in the general population (1:350) and moderately enriched in HCM (aggregate odds ratio, 14.9 [95% CI, 12.5-17.9]). Isolated LowSVs were associated with an older age of HCM diagnosis and fewer adverse events. However, LowSVs in combination with a pathogenic sarcomere variant conferred higher morbidity (eg, composite adverse event hazard ratio, 5.4 [95% CI, 3.0-9.8] versus single pathogenic sarcomere variant, 2.0 [95% CI, 1.8-2.2]; P <0.001). An intermediate functional impact was validated for 2 specific LowSVs- MYBPC3 c.442G>A (partial splice gain) and TNNT2 c.832C>T (intermediate effect on contractile mechanics). Cardiac magnetic resonance imaging analysis of the general population revealed 5 of 12 LowSVs were significantly associated with HCM-adjacent traits without overt HCM., Conclusions: This study establishes a new class of low penetrance sarcomere variants that are relatively common in the population. When penetrant, isolated LowSVs cause mild HCM. In combination with pathogenic sarcomere variants, LowSVs markedly increase disease severity, supporting a clinically significant additive effect. Last, LowSVs also contribute to age-related remodeling even in the absence of overt HCM.- Published
- 2024
- Full Text
- View/download PDF
41. Design and Rationale of the COVID Vaccine-Associated Myocarditis/Pericarditis (CAMP) Study: Short Title: Design and Rationale of the CAMP Study.
- Author
-
Truong DT, Harty BJ, Bainton J, Baker A, Bradford TT, Cai B, Coleman J, de Luise C, Dionne A, Friedman K, Gayed J, Graham E, Jone PN, Lanes S, Pearson GD, Portman MA, Powell AJ, Russell MW, Sabati AA, Taylor MD, Wheaton O, and Newburger JW
- Abstract
Background: Minimal data are available on mid- and long-term outcomes following COVID-19 vaccine-associated myocarditis/pericarditis. The COVID Vaccine-Associated Myocarditis/Pericarditis (CAMP) study aims to characterize the mid- and long-term sequelae of myocarditis/pericarditis following administration of any Pfizer-BioNTech COVID-19 vaccine (herein referred to as COMIRNATY®). Herein we describe the rationale and design of CAMP., Methods: This ongoing and actively enrolling multicenter observational cohort study across 32 North American pediatric cardiac centers will include at least 200 patients <21 years-old who presented ≤21 days from COMIRNATY® vaccination and meet the Centers for Disease Control and Prevention (CDC) case definition of probable or confirmed myocarditis/pericarditis or isolated pericarditis. The comparison cohort will consist of 100 patients <21 years-old with COVID-19 associated myocarditis/pericarditis, including those who meet the contemporaneous CDC case definition of multisystem inflammatory syndrome (MIS-C). The study will collect detailed hospital and follow-up data for up to 5 years following illness onset. Electrocardiograms, echocardiograms, and cardiac magnetic resonance (CMR) examinations will be interpreted in core laboratories. The primary outcomes are 1) composite of left ventricular ejection fraction <55% by echocardiogram, findings of myocarditis by original or revised Lake Louise criteria on CMR, and/or the presence of high-grade arrhythmias or conduction system disturbances at 6 months after myocarditis/pericarditis onset; 2) complications, such as death, and non-cardiac morbidities; and 3) patient-reported outcomes of global health, functional status, and quality of life. Analyses will include descriptive statistics and regression modeling., Current Status: Still enrolling, with 273 participants currently enrolled as of 10/16/2024 (173 vaccine-associated myocarditis/pericarditis, 100 COVID-19-associated myocarditis/pericarditis) CONCLUSIONS: With long-term follow-up and core laboratories for standardized assessments of cardiac testing, the CAMP study will make important contributions to our understanding of the mid- and long-term cardiac and non-cardiac sequelae of COVID-19 vaccine-associated myocarditis/pericarditis., Competing Interests: Declaration of competing interest This study was funded by Pfizer-BioNTech B Cai, C de Luise, J Gayed, and E Graham are employees of Pfizer, (Copyright © 2024. Published by Elsevier Inc.)
- Published
- 2024
- Full Text
- View/download PDF
42. Impact of visualising healthcare quality performance: a systematic review.
- Author
-
Yang Z, Alveyn E, Dey M, Arumalla N, Russell MD, Norton S, and Galloway JB
- Subjects
- Humans, Quality Improvement, Quality Indicators, Health Care, Quality of Health Care standards
- Abstract
Objective: Performance visualisation tools are increasingly being applied in healthcare to enhance decision-making and improve quality of care. However, there is a lack of comprehensive synthesis of their overall effectiveness and the contextual factors that influence their success in different clinical settings. This study aims to provide a broad synthesis of visualisation interventions not limited to a specific department., Design: Systematic review., Data Sources: MEDLINE and Embase were searched until December 2022., Eligibility Criteria: Randomised controlled trials (RCTs) and observational studies in English involving a visualisation intervention, either alone or as a core intervention, that reported quantitative outcomes including process and outcome indicators., Data Extraction and Synthesis: Data on study characteristics, intervention characteristics, outcome measures and results were extracted. The quality of evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation approach, and risk of bias was evaluated with Risk of Bias 2 for RCTs and Risk of Bias in Non-randomised Studies - of Interventions for non-randomised studies. RESULTS : Of the 12 studies included, 2 were RCTs and 10 were observational studies, including 1 before-after study and 1 interrupted time series study. Five studies (42%) were conducted in teaching hospital settings. Compared with the control group or baseline, 10 studies reported a statistically significant change in at least one of their outcome measures. A majority of the studies reported a positive impact, including prescription adherence (6/10), screening tests (3/10) and monitoring (3/10). Visualisation tool factors like type, clinical setting, workflow integration and clinician engagement, may have some influence on the effectiveness of the intervention, but no reliable evidence was identified., Conclusion: Performance visualisation tools have the potential to improve clinical performance indicators. More studies with standardised outcome measures and integrating qualitative methods are needed to understand the contextual factors that influence the effectiveness of these interventions., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY. Published by BMJ.)
- Published
- 2024
- Full Text
- View/download PDF
43. Temporal and regional variation in the use of biologic and targeted synthetic DMARDs for rheumatoid arthritis: a nationwide cohort study.
- Author
-
Russell MD, Yang Z, Dooley N, Gibson M, Zuckerman B, Adas MA, Alveyn E, Patel S, Bechman K, Price E, Gallagher S, Coalwood C, Cope AP, Norton S, and Galloway JB
- Abstract
Objective: To evaluate temporal and regional variation in biologic and targeted synthetic DMARD (b/tsDMARD) initiation for rheumatoid arthritis (RA) in England and Wales., Methods: An observational cohort study was conducted for people with RA enrolled in the National Early Inflammatory Arthritis Audit (NEIAA) between May 2018 and April 2022 who had 12-month follow-up data. Temporal trends in escalation to b/tsDMARDs within 12 months of initial rheumatology assessment were explored, including comparisons before and after publication (July 2021) of national guidelines that lowered the threshold for b/tsDMARD initiation to include moderate-severity RA. Case-mix-adjusted, mixed-effects regression was used to evaluate regional and hospital-level variation in b/tsDMARD initiation., Results: Of 6,098 RA patients with available follow-up, 508 (8.3%) initiated b/tsDMARDs within 12 months of initial assessment. b/tsDMARD escalation increased marginally towards the end of the study period (9.2% in May 2021/22); however, no significant differences were evident after guidelines were published permitting b/tsDMARDs for moderate-severity RA. The proportion of individuals escalated to b/tsDMARDs varied considerably between regions, ranging from 5.1% in Wales to 10.7% in North-West England. Following case-mix adjustment, the intraclass correlation (ICC) for hospitals within regions was 0.17, compared with a between-region ICC of 0.0, suggesting that the observable regional variation reflected hospital-level differences rather than systematic differences between regions themselves., Conclusion: There is marked variation in escalation to b/tsDMARDs for people newly-diagnosed with RA throughout England and Wales, despite a universal healthcare system. These disparities must be addressed if we are to deliver equitable access to b/tsDMARDs, regardless of geography., (© The Author(s) 2024. Published by Oxford University Press on behalf of the British Society for Rheumatology.)
- Published
- 2024
- Full Text
- View/download PDF
44. Factors associated with biological and targeted synthetic disease-modifying antirheumatic drug initiation for rheumatoid arthritis in underserved patient groups in England and Wales, UK: a national cohort study.
- Author
-
Russell MD, Gibson M, Zuckerman B, Kumar K, Dubey S, Adas MA, Alveyn E, Patel S, Yang Z, Bechman K, Price E, Gallagher S, Cope AP, Norton S, and Galloway JB
- Abstract
Background: Quantifying health-care inequality is essential to addressing the imbalance in outcomes attributable to age, sex, race or ethnicity, and multimorbidity. In this study, we analysed differences in the initiation of biological or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis within the universal health-care system of England and Wales, UK., Methods: An observational cohort study was conducted using the National Early Inflammatory Arthritis Audit (NEIAA) dataset. We included all patients with rheumatoid arthritis who were enrolled in NEIAA between May 8, 2018, and April 30, 2022, and who had 12-month follow-up data available. Modified Poisson regression was used to explore factors associated with the initiation of biological and targeted synthetic DMARDs within 12 months of initial rheumatology assessment. The factors evaluated included age, sex, ethnicity, socioeconomic status (index of multiple deprivation), smoking status, and relevant comorbidities (lung disease, cardiovascular disease, cancer, and depression). NEIAA is supported by people with lived experience of rheumatoid arthritis, who contributed to study design and the interpretation of findings., Findings: 6098 patients in NEIAA had new diagnoses of rheumatoid arthritis and available follow-up data. The mean age was 59·2 years (SD 14·9); 3912 (64·2%) patients were women and 2186 (35·8%) were men. 6047 (99·2%) patients had available ethnicity data, of whom 5215 (86·2%) were White, 152 (2·5%) were Black, 478 (7·9%) were Asian, and 202 (3·3%) were of mixed or other ethnicities. 508 (8·3%) of 6098 patients initiated biological and targeted synthetic DMARDs within 12 months. Patients younger than 40 years were more likely to be initiated on biological and targeted synthetic DMARDs than individuals older than 65 years (multivariable-adjusted risk ratio 2·41 [95% CI 1·83-3·19]; p<0·0001). Asian individuals were less likely to be initiated on biological and targeted synthetic DMARDs than White individuals (0·52 [0·36-0·76]; p=0·0007), which persisted after adjustment for socioeconomic status, comorbidities, baseline disease severity, and the initial response to conventional synthetic DMARDs. These differences were evident for Asian women but not Asian men. Black individuals were more likely to be initiated on biological and targeted synthetic DMARDs than White individuals (1·54 [1·10-2·16]; p=0·012), which became non-significant after adjusting for baseline disease severity and autoantibody status., Interpretation: The initiation of biological and targeted synthetic DMARDs for patients with newly diagnosed rheumatoid arthritis varies markedly by ethnicity and age in the universal health-care system of England and Wales. This study demonstrates the importance of providing tailored information and ensuring equitable access to high-quality care for underserved patient groups. The one-size-fits-all approach must be reconsidered if health disparities are to be mitigated effectively., Funding: Sandoz UK., Competing Interests: Declaration of interests JBG has received honoraria from AbbVie, Biovitrum, BMS, Celgene, Chugai, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, Roche, Sanofi, Sobi, and UCB; and grant funding from Sandoz UK. MDR has received honoraria from AbbVie, Lilly, Galapagos, Menarini, UCB, and Viforpharma; grant funding from Sandoz UK; advisory board fees from Biogen; and support for attending educational meetings from Lilly, Pfizer, Janssen, and UCB. APC has received grant funding from BMS; consulting fees from Galvani/GSK, BMS, UCB, and Janssen; honoraria from Galapagos, AbbVie, and BMS; support for attending meetings from AbbVie; and has participated in a data or advisory board for Galvani/GSK. KB has received grant funding from the National Institute for Health and Care Research; honoraria from Galapagos, UCB, and Viforpharma; and educational support from UCB. EA has received support for attending meetings from UCB. All other authors declare no competing interests., (Copyright © 2024 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
45. Physical activity in the Fontan population: provider recommendations and patient actions.
- Author
-
Pierick AR, Marshall D, Yu S, Lowery R, Glenn T, Hansen JE, Pickles D, Norris MD, Russell MW, and Schumacher KR
- Abstract
Background: Emerging evidence suggests that routine physical activity may improve exercise capacity, long-term outcomes, and quality of life in individuals with Fontan circulation. Despite this, it is unclear how active these individuals are and what guidance they receive from medical providers regarding physical activity. The aim of this study was to survey Fontan patients on personal physical activity behaviours and their cardiologist-directed physical activity recommendations to set a baseline for future targeted efforts to improve this., Methods: An electronic survey assessing physical activity habits and cardiologist-directed guidance was developed in concert with content experts and patients/parents and shared via a social media campaign with Fontan patients and their families., Results: A total of 168 individuals completed the survey. The median age of respondents was 10 years, 51% identifying as male. Overall, 21% of respondents spend > 5 hours per week engaged in low-exertion activity and only 7% spend > 5 hours per week engaged in high-exertion activity. In all domains questioned, pre-adolescents reported higher participation rates than adolescents. Nearly half (43%) of respondents reported that they do not discuss activity recommendations with their cardiologist., Conclusions: Despite increasing evidence over the last two decades demonstrating the benefit of exercise for individuals living with Fontan circulation, only a minority of patients report engaging in significant amounts of physical activity or discussing activity goals with their cardiologist. Specific, individualized, and actionable education needs to be provided to patients, families, and providers to promote and support regular physical activity in this patient population.
- Published
- 2024
- Full Text
- View/download PDF
46. Association between interleukin-12 p40 subunit and risk of primary Sjögren's syndrome: a Mendelian randomization study.
- Author
-
Zuckerman BP, Yang Z, Warwick A, Wincup C, Russell M, Galloway JB, and Zhao SS
- Abstract
Objectives: Interleukin-12 (IL-12) signalling was proposed in the immunopathogenesis of primary Sjögren's disease. The efficacy of therapies targeting this pathway is currently unclear. Herein, we investigated the associations between circulating proteins involved in the IL-12 and IL-23 signalling pathways on primary Sjögren's disease using mendelian randomization., Methods: We selected SNPs from protein quantitative trait loci of IL12A, IL12B, IL12Rβ1, IL12Rβ2, and IL23R to examine the association between alterations in their levels and risk of primary Sjögren's disease. Genetic association data for proteins were taken from studies ranging from 3,301-54 306 in sample size, and from 3,232 cases of primary Sjögren's disease and 17 481 controls. The Wald ratio or inverse variance weighted methods estimated causal effects. We applied colocalization and pleiotropy-robust methods as sensitivity analyses for confounding., Results: There was a negative association between genetically predicted IL-12p40 (encoded by IL12B) and primary Sjögren's disease. In the two independent exposure datasets odds ratio (OR) 0.79 (95% confidence interval [CI] 0.68-0.93; P-value = 0.004) and OR 0.86 (95% CI 0.78-0.95; P-value = 0.003) per standard deviation decrease in genetically predicted IL-12p40. Neither IL-12Rβ2 and IL-23R met the threshold P-value after MR analyses (P-value < 0.01) for colocalization assessment. No variants for the IL12A gene met prerequisite thresholds for weak instrument bias., Conclusion: This study provides genetic evidence that IL-12p40 has a causal role in primary Sjögren's disease pathogenesis. Our data suggest that decreasing levels of IL-12p40 may be deleterious. We would not suggest selecting this drug target as a therapeutic option., (© The Author(s) 2024. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
47. Researching COVID to enhance recovery (RECOVER) pediatric study protocol: Rationale, objectives and design.
- Author
-
Gross RS, Thaweethai T, Rosenzweig EB, Chan J, Chibnik LB, Cicek MS, Elliott AJ, Flaherman VJ, Foulkes AS, Gage Witvliet M, Gallagher R, Gennaro ML, Jernigan TL, Karlson EW, Katz SD, Kinser PA, Kleinman LC, Lamendola-Essel MF, Milner JD, Mohandas S, Mudumbi PC, Newburger JW, Rhee KE, Salisbury AL, Snowden JN, Stein CR, Stockwell MS, Tantisira KG, Thomason ME, Truong DT, Warburton D, Wood JC, Ahmed S, Akerlundh A, Alshawabkeh AN, Anderson BR, Aschner JL, Atz AM, Aupperle RL, Baker FC, Balaraman V, Banerjee D, Barch DM, Baskin-Sommers A, Bhuiyan S, Bind MC, Bogie AL, Bradford T, Buchbinder NC, Bueler E, Bükülmez H, Casey BJ, Chang L, Chrisant M, Clark DB, Clifton RG, Clouser KN, Cottrell L, Cowan K, D'Sa V, Dapretto M, Dasgupta S, Dehority W, Dionne A, Dummer KB, Elias MD, Esquenazi-Karonika S, Evans DN, Faustino EVS, Fiks AG, Forsha D, Foxe JJ, Friedman NP, Fry G, Gaur S, Gee DG, Gray KM, Handler S, Harahsheh AS, Hasbani K, Heath AC, Hebson C, Heitzeg MM, Hester CM, Hill S, Hobart-Porter L, Hong TKF, Horowitz CR, Hsia DS, Huentelman M, Hummel KD, Irby K, Jacobus J, Jacoby VL, Jone PN, Kaelber DC, Kasmarcak TJ, Kluko MJ, Kosut JS, Laird AR, Landeo-Gutierrez J, Lang SM, Larson CL, Lim PPC, Lisdahl KM, McCrindle BW, McCulloh RJ, McHugh K, Mendelsohn AL, Metz TD, Miller J, Mitchell EC, Morgan LM, Müller-Oehring EM, Nahin ER, Neale MC, Ness-Cochinwala M, Nolan SM, Oliveira CR, Osakwe O, Oster ME, Payne RM, Portman MA, Raissy H, Randall IG, Rao S, Reeder HT, Rosas JM, Russell MW, Sabati AA, Sanil Y, Sato AI, Schechter MS, Selvarangan R, Sexson Tejtel SK, Shakti D, Sharma K, Squeglia LM, Srivastava S, Stevenson MD, Szmuszkovicz J, Talavera-Barber MM, Teufel RJ 2nd, Thacker D, Trachtenberg F, Udosen MM, Warner MR, Watson SE, Werzberger A, Weyer JC, Wood MJ, Yin HS, Zempsky WT, Zimmerman E, and Dreyer BP
- Subjects
- Humans, Adolescent, Child, Child, Preschool, Female, Young Adult, Adult, Male, Infant, SARS-CoV-2 isolation & purification, Infant, Newborn, Prospective Studies, Research Design, Cohort Studies, Post-Acute COVID-19 Syndrome, COVID-19 epidemiology, COVID-19 virology
- Abstract
Importance: The prevalence, pathophysiology, and long-term outcomes of COVID-19 (post-acute sequelae of SARS-CoV-2 [PASC] or "Long COVID") in children and young adults remain unknown. Studies must address the urgent need to define PASC, its mechanisms, and potential treatment targets in children and young adults., Observations: We describe the protocol for the Pediatric Observational Cohort Study of the NIH's REsearching COVID to Enhance Recovery (RECOVER) Initiative. RECOVER-Pediatrics is an observational meta-cohort study of caregiver-child pairs (birth through 17 years) and young adults (18 through 25 years), recruited from more than 100 sites across the US. This report focuses on two of four cohorts that comprise RECOVER-Pediatrics: 1) a de novo RECOVER prospective cohort of children and young adults with and without previous or current infection; and 2) an extant cohort derived from the Adolescent Brain Cognitive Development (ABCD) study (n = 10,000). The de novo cohort incorporates three tiers of data collection: 1) remote baseline assessments (Tier 1, n = 6000); 2) longitudinal follow-up for up to 4 years (Tier 2, n = 6000); and 3) a subset of participants, primarily the most severely affected by PASC, who will undergo deep phenotyping to explore PASC pathophysiology (Tier 3, n = 600). Youth enrolled in the ABCD study participate in Tier 1. The pediatric protocol was developed as a collaborative partnership of investigators, patients, researchers, clinicians, community partners, and federal partners, intentionally promoting inclusivity and diversity. The protocol is adaptive to facilitate responses to emerging science., Conclusions and Relevance: RECOVER-Pediatrics seeks to characterize the clinical course, underlying mechanisms, and long-term effects of PASC from birth through 25 years old. RECOVER-Pediatrics is designed to elucidate the epidemiology, four-year clinical course, and sociodemographic correlates of pediatric PASC. The data and biosamples will allow examination of mechanistic hypotheses and biomarkers, thus providing insights into potential therapeutic interventions., Clinical Trials.gov Identifier: Clinical Trial Registration: http://www.clinicaltrials.gov. Unique identifier: NCT05172011., Competing Interests: I have read the journal’s policy and the authors of this manuscript have the following competing interests: Brett Anderson reported receiving direct support for work not related to RECOVER work/publications from Genentech and the National Institute of Allergy and Immunology. Walter Dehority reported receiving grant support from Merck and participating in research for the Moderna COVID-19 pediatric vaccine trial and the Pfizer Paxlovid trial. Alex Fiks reported receiving support from NJM insurance and personal consulting fees not related to this paper from Rutgers University and the American Academy of Pediatrics. Ashraf Harahsheh reported serving as a scientific advisory board member unrelated to this paper for OP2 DRUGS. Lawrence Kleinman reported serving as an unpaid member of the Board of Directors for the DARTNet Institute, as a principle investigator at Quality Matters, Inc., and as the Vice Chair for the Borough of Metuchen Board of Health. Dr. Kleinman also reported grant support for work not related to RECOVER work/publications from NIH, HRSA, and the Robert Wood Johnson Foundation. Dr. Kleinman also reported minority individual stock ownership in Apple Computer, Sanofi SA, Experion, GlaxoSmithKline, Magyar Bank, Regeneron Pharmaceuticals, JP Morgan Chase, and Amgen Inc. Torri Metz reported participating as a Principle Investigator in the medical advisory board for the planning of a Pfizer clinical trial of SARS-CoV-2 vaccination in pregnancy. She is also a principle investigator for a Pfizer study evaluating the pharmacokinetics of Paxlovid in pregnant people with COVID-19. Joshua Milner reported serving as a member of the Scientific Advisory Board for Blueprint Medicines, in a capacity unrelated to RECOVER work/publications. This does not alter our adherence to PLOS ONE policies on sharing data and materials., (Copyright: © 2024 Gross et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.